Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 161
2 55
1 24
NEB 4
Curative setting
A 59
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 23
Gastrointestinal Cancers 76
Genitourinary Cancers 71
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 3
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 17
Genitourinary Cancers 5
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 13
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Mirvetuximab soravtansine - Paclitaxel, pegylated liposomal doxorubicin, or topotecan. (Investigator’s choice of chemotherapy) Mirvetuximab soravtansine for adult patients with FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1-3 prior systemic treatment regimens MIRASOL, Study 0416
    Gynaecological Malignancies
    		 Epithelial ovarian, fallopian tube or primary peritoneal cancer FRalpha positive MIRASOL, Study 0416

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Enzalutamide - Placebo + Leuprolide As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy . Monotherapy group EMBARK
    Genitourinary Cancers
    		 Prostate cancer PSA doubling time ≤ 9 month EMBARK

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Trastuzumab deruxtecan - Single arm Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options DESTINY-Lung01
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer HER2 (IHC 3+) DESTINY-Lung01

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Trastuzumab deruxtecan - Single arm Trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options DESTINY-PanTumor02
    Tumour agnostic
    		 - HER2 (IHC 3+) DESTINY-PanTumor02

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Alectinib - Platinum-Based ChT Alectinib for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer ALINA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK positive ALINA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Nogapendekin alfa inbakicept Bacillus Calmette-Guérin (BCG) Single arm Nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (Ta/T1; Cohort A) QUILT-3.032
    Genitourinary Cancers
    		 Urothelial Carcinoma BCG-unresponsive QUILT-3.032

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Talazoparib Enzalutamide Placebo + enzalutamide Talazoparib with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALAPRO-2
    Genitourinary Cancers
    		 Prostate cancer HRR gene-mutated TALAPRO-2

    3

    PRELIMINARY SCORE

    • rPFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Repotrectinib - Single arm FDA: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. First FDA approval that includes patients with ROS1-positive NSCLC who are TKI naïve. EMA: Repotrectinib as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) who are TKI naïve. TRIDENT-1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ROS1-positive (TKI naïve) TRIDENT-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Sugemalimab Platinum-based chemotherapy Placebo + platinum-containing chemotherapy Sugemalimab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy GEMSTONE-302
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - GEMSTONE-302

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Tarlatamab - Single arm Tarlatamab treatment for the extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (10mg) DeLLphi-301
    Thoracic Malignancies
    		 Small-cell lung cancer - DeLLphi-301

    2

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      2
    Repotrectinib - Single arm FDA: Repotrectinib used for locally advanced or metastatic ROS1-positive non-small cell lung cancer. FDA approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor (TKI). EMA: Repotrectinib as monotherapy is indicated for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) who have previously received a ROS1 tyrosine kinase inhibitor (TKI). TRIDENT-1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ROS1-positive (previously received TKI) TRIDENT-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Atezolizumab - Single arm For adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Study ML39345
    Sarcoma
    		 Alveolar soft part - Study ML39345

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Melphalan - Single arm A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation FOCUS
    Skin Cancers
    		 Uveal melanoma - FOCUS

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Adagrasib Cetuximab Single arm Adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-based ChT KRYSTAL-1
    Gastrointestinal Cancers
    		 Colorectal Cancer KRAS G12C-mutated KRYSTAL-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Tislelizumab Carboplatin + paclitaxel (Arm A) Carboplatin + paclitaxel (Arm C) Tislelizumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC RATIONALE 307
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - Squamous cell - RATIONALE 307

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Tislelizumab Carboplatin + nab-paclitaxel (Arm B) Paclitaxel + Carboplatin (Arm C) Tislelizumab in combination with carboplatin and nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC. RATIONALE 307
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - Squamous cell - RATIONALE 307

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Durvalumab Carboplatin, paclitaxel plus Olaparib Carboplatin, paclitaxel, and placebo (arm A) Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR) DUO-E
    Gynaecological Malignancies
    		 Endometrial Cancer - DUO-E

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Durvalumab Carboplatin and paclitaxel Carboplatin, paclitaxel, and placebo (arm A) FDA: Durvalumab is indicated with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). EMA: Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) DUO-E
    Gynaecological Malignancies
    		 Endometrial Cancer - DUO-E

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pembrolizumab Carboplatin and paclitaxel Carboplatin, paclitaxel, and placebo Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with dMMR) KEYNOTE-868/NRG-GY018
    Gynaecological Malignancies
    		 Endometrial Cancer dMMR KEYNOTE-868/NRG-GY018

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pembrolizumab Carboplatin and paclitaxel Carboplatin, paclitaxel, and placebo Pembrolizumab with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. (Cohort data with pMMR) KEYNOTE-868/NRG-GY018
    Gynaecological Malignancies
    		 Endometrial Cancer - KEYNOTE-868/NRG-GY018

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Toripalimab Paclitaxel + cisplatin Placebo + paclitaxel + cisplatin Toripalimab, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. JUPITER-06
    Gastrointestinal Cancers
    		 Oesophageal squamous cell carcinoma - JUPITER-06

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Zolbetuximab Fluoropyrimidine and platinum containing ChT Placebo plus CAPOX Zolbetuximab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive. GLOW
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER2 negative, CLDN18.2 positive GLOW

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Amivantamab Carboplatin + Pemetrexed Carboplatin + Pemetrexed Amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). MARIPOSA-2
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR Exon 19 deletions or Exon 21 L858R substitution mutations MARIPOSA-2

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Atezolizumab - Vinorelbine or gemcitabine (by investigator choice ) Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy IPSOS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - IPSOS

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pembrolizumab Chemoradiotherapy (Cisplatin) Placebo + Chemoradiotherapy (Cisplatin) FDA: Pembrolizumab with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer. EMA: Pembrolizumab, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. ENGOT-cx11/GOG-3047/KEYNOTE-A18
    Gynaecological Malignancies
    		 Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18

    A

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    TTFields (NovoTTF-100A) Temozolomide Temozolomide The medical device, the NovoTTF-100A indicated for use in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed GBM following surgery, chemotherapy, and radiation therapy EF-14
    Brain Tumours
    		 Glioblastoma - EF-14

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Vorasidenib - Placebo Vorasidenib, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection INDIGO
    Brain Tumours
    		 Glioma (low grade). (Grade 2 astrocytoma or oligodendroglioma) IDH1 or IDH2 mutation INDIGO

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Afamitresgene autoleucel - Single arm Afamitresgene autoleucel, a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumour expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices SPEARHEAD-1
    Sarcoma
    		 Soft tissue - synovial sarcoma HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and MAGE-A4 Ag positive SPEARHEAD-1

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Dostarlimab Carboplatin + paclitaxel Placebo + carboplatin + paclitaxel FDA: Dostarlimab with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adult patients with primary advanced or recurrent endometrial cancer (EC). EMA: Dostarlimab is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. RUBY
    Gynaecological Malignancies
    		 Endometrial Cancer - RUBY

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Amivantamab + lazertinib - Osimertinib FDA: Amivantamab in combination with lazertinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. EMA: Amivantamab in combination with lazertinib is indicated for the first‑line treatment of adult patients with advanced non‑small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. MARIPOSA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR Exon 19 deletions or Exon 21 L858R substitution mutations MARIPOSA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.